BNP Paribas Financial Markets Raises Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP)

BNP Paribas Financial Markets boosted its position in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) by 32.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,965 shares of the company’s stock after buying an additional 5,397 shares during the period. BNP Paribas Financial Markets owned 0.07% of ArriVent BioPharma worth $516,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in AVBP. AlphaCentric Advisors LLC boosted its stake in shares of ArriVent BioPharma by 3.6% in the second quarter. AlphaCentric Advisors LLC now owns 86,000 shares of the company’s stock worth $1,595,000 after acquiring an additional 3,000 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of ArriVent BioPharma by 31.4% during the second quarter. Bank of New York Mellon Corp now owns 29,847 shares of the company’s stock worth $554,000 after buying an additional 7,140 shares in the last quarter. Rhumbline Advisers raised its position in shares of ArriVent BioPharma by 30.1% in the second quarter. Rhumbline Advisers now owns 12,707 shares of the company’s stock valued at $236,000 after buying an additional 2,942 shares during the last quarter. Novo Holdings A S raised its position in shares of ArriVent BioPharma by 39.3% in the second quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock valued at $27,825,000 after buying an additional 422,860 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of ArriVent BioPharma in the third quarter worth about $280,000. Institutional investors and hedge funds own 9.48% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on AVBP shares. Citigroup boosted their target price on ArriVent BioPharma from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. The Goldman Sachs Group upped their target price on ArriVent BioPharma from $28.00 to $38.00 and gave the company a “buy” rating in a report on Tuesday, September 10th. HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of ArriVent BioPharma in a report on Friday, November 15th. Finally, Oppenheimer reissued an “outperform” rating and issued a $39.00 price objective (up previously from $35.00) on shares of ArriVent BioPharma in a report on Tuesday, September 10th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $36.80.

ArriVent BioPharma Stock Up 3.2 %

Shares of ArriVent BioPharma stock opened at $26.72 on Friday. The business’s fifty day simple moving average is $29.48 and its 200-day simple moving average is $24.39. ArriVent BioPharma, Inc. has a 52 week low of $14.35 and a 52 week high of $36.37.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.